Blue-Chip

Book Profits on This NYSE-Listed Tobacco Major – BTI

March 01, 2022 | Team Kalkine
Book Profits on This NYSE-Listed Tobacco Major – BTI

 

British American Tobacco PLC

British American Tobacco PLC (NYSE: BTI) is a British multinational corporation that produces and sells cigarettes, tobacco, and other nicotine-containing products. Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans Neo, Vuse, Newport, Camel, and Natural American Spirit are among the company's leading brands. BTI has 2.29 billion American Depository Shares (ADS) listed and outstanding (each ADS representing one ordinary shares).

Why should Investors Book Profits?

  • Long Cash Conversion Days: At the end of December 31, 2021, the company's cash conversion days were 527.0 days, compared to the industry median of 89.1 days, implying that the company takes a long time to convert its inventory to cash.
  • Leveraged Balance Sheet: As of December 31, 2021, the company's debt/equity ratio was 0.59x, compared to the industry median of 0.20x. As a result, the company's exposure to balance-sheet risk has increased.
  • Decline in Sticks Equivalents: According to the company, traditional oral stick volumes fell 3.9% YoY to 8.0 billion sticks equivalent in FY21. In addition, total combustible sticks volumes fell 0.30% YoY to 655 billion sticks equivalent during the same period.
  • Regulatory & Taxation Risk: Tobacco manufacturers are required to comply with various regulatory regimes around the world, making the industry highly regulated. These restrictions may limit BTI's capacity to market its products, jeopardizing the company's and financial health. Furthermore, BTI is sensitive to unanticipated and severe increases in tobacco and nicotine-related taxes in its main markets, which might significantly impact its revenues and results of operations.

 Valuation Methodology: EV/EBITDA Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

Stock Recommendation:

BTI's share price has surged 31.80% in the past three months and is currently leaning towards the higher end of its 52-week range of USD 33.62 to USD 47.24. We have valued the stock using the EV/EBITDA multiple-based relative valuation methodology and arrived at a target price of USD 40.16.

Considering the significant rise in the share price in a short span, long cash conversion cycle, the decline in sticks equivalent, and other induced regulatory risks in the business, we recommend a "Sell" rating on the stock at the closing price of USD 45.18, up 3.46% as of February 25, 2022.

Three-Year Technical Price Chart (as of February 25, 2022). Source: REFINITIV, Analysis by Kalkine Group 

*All forecasted figures and Industry Information have been taken from REFINITIV.

*The reference data in this report has been partly sourced from REFINITIV.


Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.